Table 2.

Lymphocyte and monocyte subpopulations

Cell subset category	Subpopulations (%)	PI Monotherapy (n=40)	IP-containing triple therapy (n=20)	p
Activation of CD4 and CD8 T cells	CD4 DR+38+	2.23 (1.59–3.73)	2.62 (1.57–3.91)	0.5483
	CD8 DR+38+	8.3 (5.2–12.62)	8.33 (6.01–14.73)	0.8525
Senescence	CD4 28−57+	1.73 (0.64–3.55)	2.63 (0.83–5.18)	0.3944
	CD8 28−57+	28.09 (18.19–39.97)	31.71 (26.87–43.95)	0.2363
Exhaustion	CD4 PD1+	20.54 (14.02–30.33)	18.65 (16.58–27.56)	0.7212
	CD8 PD1+	22.72 (18.38–31.35)	25.30 (21.29–29.52)	0.4605
Co-receptors	CD4 CCR5+	25.22 (12.59–38.26)	24.63 (15.13–29.36)	0.7030
	CD8 CCR5+	14.66 (7.42–26.77)	16.85 (6.59–23.24)	0.8839
Differentiation stage	CD4 RA+RO−	31.27 (24.41–48.34)	31.88 (21.13–40.84)	0.9032
	CD8 RA+RO−	46.40 (36.09–54.47)	45.60 (36.38–54.45)	0.9677
	CD4 RA-RO+	57.51 (40.77–69.30)	57.81 (35.94–63.45)	0.5008
	CD8 RA-RO+	40.06 (28.49–52.23)	39.69 (25.29–47.85)	0.5647
Monocyte activation	CD14+16+163+	9.63 (3.65–15.62)	7.53 (3.23–9.09)	0.033
	CD14+16−163+	55.17 (31.58–71.76)	33.57 (20.00–53.53)	0.031
	CD14+16+163−	13.51 (10.81–21.71)	12.04 (9.88–15.97)	0.1518
	CD14+16+	26.85 (18.99–41.06)	19.79 (14.94–25.88)	0.029